spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  glycosaminoglycan 

 HSMN NewsFeed - 28 Jan 2026
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
Regenerative Medicine FDA
 HSMN NewsFeed - 6 Feb 2024
FDA Clears Groundbreaking Corplex P(TM): The First Human Umbilical Cord-Derived Medical Device
Devices Wound Care FDA
 HSMN NewsFeed - 29 Jun 2018
Ultragenyx Announces Positive CHMP Opinion for Mepsevii(TM) (vestronidase alfa) For the Treatment of Mucopolysaccharidosis VII
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Sep 2017
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 23 May 2017
Ultragenyx Announces Recombinant Human Beta-Glucuronidase Biologics License Application and Marketing Authorization Application Filed and Accepted for Review; FDA Grants Priority Review Status
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Jun 2016
Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Feb 2016
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Jan 2016
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 23 Jul 2014
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 25 Mar 2014
Integra LifeSciences Launches Integra(R) Wound Matrix (Thin)
Devices Wound Care Product Launch
 HSMN NewsFeed - 24 Oct 2013
Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jan 2011
Stellar Pharmaceuticals Annouces the Approval of Uracyst(R) by the KFDA in South Korea
Biopharmaceuticals Urology Regulatory
 HSMN NewsFeed - 30 Jul 2010
Stellar Pharmaceuticals Inc. Signs Agreement for Distribution and Sale of Uracyst(R) in Spain
Biopharmaceuticals Distribution
 HSMN NewsFeed - 5 May 2010
Stellar Pharmaceuticals Signs Licensing Agreement for Distribution and Sale of Uracyst(R) in Portugal
Biopharmaceuticals Urology Licensing Distribution
 HSMN NewsFeed - 5 May 2009
Stellar Pharmaceuticals Inc. Signs Licensing Agreement for Distribution and Sale of Uracyst(R) in Italy
Biopharmaceuticals Urology Licensing Distribution
 HSMN NewsFeed - 8 Jan 2009
Stellar Pharmaceuticals Inc. Signs Licensing Agreement for Distribution and Sale of Uracyst(R) in Netherlands, Belgium and Luxemburg
Biopharmaceuticals Urology Distribution
 HSMN NewsFeed - 9 Dec 2008
Stellar Pharmaceuticals Inc. Signs Licensing Agreement For Distribution and Sale of Uracyst(R) in United Kingdom and Ireland
Biopharmaceuticals Urology Distribution
 HSMN NewsFeed - 13 Nov 2008
Wound Management Technologies, Inc. Announces FDA Clearance of 510k
Devices Wound Care FDA
 HSMN NewsFeed - 27 May 2008
Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 31 Mar 2008
Naglazyme Approved by Japanese Ministry of Health
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Feb 2008
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Feb 2008
Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 13 Dec 2007
Integra LifeSciences Launches Flowable Wound Matrix
Devices Wound Care
 HSMN NewsFeed - 6 Dec 2007
Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
Biopharmaceuticals
 HSMN NewsFeed - 4 Oct 2007
Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Jun 2007
Shire's ELAPRASE(TM) (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Feb 2007
Integra LifeSciences Launches TenoGlide Tendon Protector Sheet
Devices FDA
 HSMN NewsFeed - 11 Jan 2007
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Jan 2007
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Dec 2006
Stellar Pharmaceuticals Signs License and Supply Agreements With Watson Pharmaceuticals for Stellar's Uracyst'R' Product
Biopharmaceuticals Urology Licensing
 HSMN NewsFeed - 19 Oct 2006
ELAPRASE(TM) (idursulfase) Receives Positive Opinion in Europe
Biopharmaceuticals Regulatory
Return to NewsFeed  

 Additional items found! 30

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 30 additional stories matching:
glycosaminoglycan
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!